PROJECT VISION, is a multi-year initiative to position diabetes educators for success within a dynamically changing environment, elevating our role as integrators for clinical management, education, prevention and support.
I was able to attend the AADE National Advocacy Forum in Chicago in May It’s purpose was to give attendees most up to date information on bills before Congress that are pertinent to persons with diabetes and diabetes educators. Read to learn more.
In November 2016, the FDA approved a new combination drug for type 2 diabetes mellitus, Soliqua®. Soliqua® 100/33 injection is a combination of insulin glargine (100 units/mL) and glucagon-like peptide-1 (GLP-1) receptor agonist, lixisenatide (33 mcg/mL)